1.35 m babies are born with a congenital heart defect each year. Of these, 400,000 have heart valve defects, but there is no durable valve replacement on the market! We are fulfilling that unmet clinical need with a completely new prosthetic valve for adults and children, implanted using a low-risk transcatheter technique. Our valve is made from patient-donated (endogenous) tissue, giving it lifelong durability: a once-in-a-lifetime solution that is affordable for patients and healthcare providers worldwide.Learn more
GrOwnValve is a pre-clinical stage medical device company, developing a unique heart valve prosthesis system. The first product, the AdultValve and the second product, the ChildValve including a bioresorbable anchoring device will come to market as a procedure pack that enables a safe, affordable and easy-to-use minimally invasive heart valve replacement made from the patient’s own tissue.
Our main goal is to offer a lifelong cure to patients with heart valve defects worldwide. Our innovation eliminates the need for repeated heart valve replacement surgery and lifelong medication.
paediatric cardiologist, clinical trial
paediatric cardiac surgeon, clinical trial
regulatory compliance and quality control
engineer 3D technology
In july 2018 the GrOwnValve Project Team won the BPW Canvas business plan price by the IBB Berlin.
In 2019 Spark helped kick-start the bioresorbable stent solution to make the GrOwnValve innovation a possible treatment for small (growing) patients.
We are very happy to be nominated #ScienceBreakthrough of the year by the Falling Walls Foundation award!
In Autumn of 2017 the GrOwnValve Project was rewarded the EXIST translational grant to bring the innovative technology into preclinical testing.
We are very proud to have been able to be part of the research consortium that was able to reach a Sciencemag publication.